Oxelumab

Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma[1].

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

Oxelumab (10 μg/mL; 3 d) represses cell proliferation of NK cells[2]. Cell Proliferation Assay[2] Cell Line: Natural Killer (NK) cell lines Concentration: 10 μg/mL Incubation Time: 3 days Result: Inhibited cell proliferation of NK cells.

Oxelumab (5 and 30 mg/kg; i.p., once daily for twice) affects the concentrations of IL-6 and the frequencies of splenic human effector memory T cells and switched B cells[1]. Animal Model: NSG mice with PBMCs from UC patients with simple clinical colitis activity index (SCCAI)[1] Dosage: 5 and 30 mg/kg Administration: Intraperitoneal injectionon; 5 and 30 mg/kg, once daily, on days 6 and 13 Result: Reversed the ethanol-induced colon dilated and the lost of distinct pattern of pellets. Decreased the level of IL-6 and increased the concentrations of glutamic acid. Reduced frequencies of splenic human effector memory T cells and switched B cells.

[1]. Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int Arch Allergy Immunol. 2019;180(2):91-102.  

[2]. Kweon S, et al. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21. Front Immunol. 2019 Apr 24;10:879.